PTK2 and glioblastoma: In the past few years, pharmacological approaches aiming at dampening GBM invasiveness showed promising results in vitro, in mouse models or in clinical trials and targeted metalloproteinases [74,75,76], integrins [77], cytoskeleton reorganization [78], or signaling molecules such as FAK [79,80,81] and SRC [82,83,84,85].